A 48-year-old woman with type 2 diabetes mellitus on metformin monotherapy (HbA1c 7.8%) develops acute kidney injury (eGFR drops to 28 mL/min/1.73m²). Metformin is contraindicated. She has no contraindications to sulfonylureas or DPP-4 inhibitors. What is the drug of choice for glycemic control in this setting?

Explanation

## Management of Type 2 Diabetes in Renal Impairment **Key Point:** When metformin is contraindicated due to renal impairment (eGFR <30), DPP-4 inhibitors (e.g., vildagliptin) are preferred over sulfonylureas because they have minimal renal excretion, no hypoglycemia risk, and are weight-neutral [cite:Harrison 21e Ch 417]. ### Why Metformin is Contraindicated Here - eGFR 28 mL/min/1.73m² is below the safety threshold (typically eGFR <30) - Risk of **metformin-associated lactic acidosis (MALA)** increases significantly - Metformin accumulates in renal failure due to reduced clearance ### Comparison of Alternatives in Renal Impairment | Drug | Renal Clearance | Hypoglycemia Risk | Weight Effect | Renal Safety | |---|---|---|---|---| | **Vildagliptin** | Minimal (~20%) | None | Neutral | **Safe** | | Glibenclamide | Hepatic | **HIGH** | Gain | Unsafe (accumulation) | | Pioglitazone | Hepatic | None | Gain | Safe but not preferred | | Acarbose | Renal | None | Neutral | **Contraindicated** (eGFR <30) | **High-Yield:** DPP-4 inhibitors (sitagliptin, vildagliptin, saxagliptin) are the safest monotherapy alternatives when metformin is contraindicated in renal disease [cite:KD Tripathi 8e Ch 24]. ### Mechanism of Vildagliptin 1. Inhibits dipeptidyl peptidase-4 (DPP-4) 2. Increases GLP-1 and GIP levels 3. Enhances glucose-dependent insulin secretion 4. Suppresses glucagon in hyperglycemic state 5. **No hypoglycemia when used alone** (glucose-dependent mechanism) **Clinical Pearl:** Vildagliptin is particularly advantageous in renal impairment because it undergoes hepatic metabolism and minimal renal excretion, unlike many other agents. ### Why Other Options Fail - **Glibenclamide:** Sulfonylureas accumulate in renal failure and cause severe, prolonged hypoglycemia. Contraindicated in eGFR <30. - **Pioglitazone:** While renally safe, it causes weight gain and fluid retention—not ideal as monotherapy in this setting. - **Acarbose:** Alpha-glucosidase inhibitors are contraindicated in eGFR <30 due to accumulation of active metabolites and GI side effects.